An authoritative view on how pharma companies can improve access to medicine

Our team has a unique window into Big Pharma’s approach to access to medicine, and works with leading thinkers on global health and on the industry. This puts us in an unrivalled position to cut through the debates with new perspectives on how the industry can bring medicine to the most people. o share our thinking, browse through the viewpoints and articles we have written for leading news outlets and magazines.

Harvard Business Review: How Pharma Can Fix Its Reputation And Its Business At The Same Time

Harvard Business Review: How Pharma Can Fix Its Reputation and Its Business at the Same Time

Could transforming access to medicine to a fully-fledged business strategy help pharma companies enhance shareholder value? Damiano de Felice examines in his article for Harvard Business Review.
Continue reading
Toward 2021: Spurring The Pharma Industry To Reach “the 2 Billion To Go”

Toward 2021: spurring the pharma industry to reach “the 2 billion to go”

What direction do we plan to take in the coming 5 years? Jayasree K. Iyer, Executive Director, Access to Medicine Foundation shares the next steps and strategic goals for the organisation to achieve by 2021
Continue reading
Access To Mental Healthcare: How Should Pharma Companies Channel Their Efforts?

Access to mental healthcare: how should pharma companies channel their efforts?

Suvi Karuranga, Researcher, and Jayasree K. Iyer, Executive Director, share their thoughts and findings on access to mental healthcare with the aim of starting a conversation about how manufacturers’ efforts can be channeled in the best directions, and to identify where more can be done.
Continue reading
Shifting Mindsets To Improve Access To Medicine

Shifting mindsets to improve access to medicine

In the article, Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation, describes the corporate strategies that large pharmaceutical companies use to make medicines and vaccines accessible for people living in low- and middle-income countries. In this piece, she identifies the steps that companies can and typically do take when creating an effective access-to-medicine strategy.
Continue reading
Ensuring Sustained Incentives For Pharma To Develop Medicine For The Poor

Ensuring sustained incentives for pharma to develop medicine for the poor

A commentary by Clarke B. Cole and Jayasree K. Iyer, exploring the progress made by major pharmaceutical companies in collaborating to innovate products for diseases of poverty, and the success of R&D models in incentivising these contributions.
Continue reading
Fighting The Trade In Falsified Medical Products: Building A Consensus On The Role For The Private Sector

Fighting the trade in falsified medical products: building a consensus on the role for the private sector

In their article, Laurien Rook, Researcher, and Danny Edwards, Research Programme Manager at the Access to Medicine Foundation, highlight the ongoing threat falsified medical products pose to global health, and describe the various actions companies take in addressing this issue.
Continue reading
Pharmaceutical Companies Donating Medicines In Crisis Situations

Pharmaceutical companies donating medicines in crisis situations

In the article, Catherine Gray and Suvi Karuranga, Researchers at the Access to Medicine Foundation, discuss the role of pharmaceutical companies in coordinated humanitarian responses to crisis situations.
Continue reading
Stanford Social Innovation Review: Access By Prescription

Stanford Social Innovation Review: Access by Prescription

In the article, Jayasree K. Iyer, Executive Director at the Access to Medicine Foundation, describes the corporate strategies that large pharmaceutical companies use to make medicines and vaccines accessible for people living in low- and middle-income countries. In this piece, she identifies the steps that companies can and typically do take when creating an effective access-to-medicine strategy.
Continue reading
Reaching The 2 Billion: The Japanese Pharmaceutical Industry And Access To Medicine

Reaching the 2 billion: The Japanese pharmaceutical industry and access to medicine

A commentary by Jayasree K. Iyer and Danny Edwards, on the increasing orientation of Japan towards global health issues, and the growing contribution of the the Japanese pharmaceutical industry towards achieving access to medicine goals.
Continue reading
Access To Hepatitis C Medicine

Access to hepatitis C medicine

The Bulletin of the World Health Organization has published the latest study from the Access to Medicine Foundation: on how the world’s largest pharma companies are improving access to hepatitis C treatment.
Continue reading
The R&D Agenda And How It Addresses Access To Vaccines

The R&D agenda and how it addresses access to vaccines

The article examines the current state of the vaccine pipeline and how large pharmaceutical companies are considering access to these products.
Continue reading
SDG SERIES: The Access To Medicine Index And Accountability Of Pharmaceutical Companies

SDG SERIES: The Access to Medicine Index and Accountability of Pharmaceutical Companies

Suvi Karuranga, Researcher, and Jayasree K. Iyer, Executive Director, share their thoughts and findings on access to mental healthcare with the aim of starting a conversation about how manufacturers’ efforts can be channeled in the best directions, and to identify where more can be done.
Continue reading
Are Pharma Giants Living Up To Big Promises On Development?

Are pharma giants living up to big promises on development?

In the article, the authors write about how pharmaceutical companies are taking action to improve maternal health, and make the case for tracking corporations as well as governments when it comes to meeting global development targets.
Continue reading
Medicin. Novo Sikrer Ulandenes Adgang

Medicin. Novo sikrer ulandenes adgang

Danish newspaper Politiken publishes a piece by Jayasree K. Iyer, the Index's Head of Research, and Damiano de Felice, Strategy. They give an overview of how Novo Nordisk performs in the 2014 Access to Medicine Index, and how the Danish pharma sector can address access to medicine.
Continue reading
Big Pharma And Social Responsibility — The Access To Medicine Index

Big Pharma and Social Responsibility — The Access to Medicine Index

The article sets out the methods of the Access to Medicine Index, touching upon the 2012 Index’ key findings and trends. Moreover, Professor Hogerzeil highlights the value of the Index, emphasizing the movement of companies towards fulfilling, in his own words, the “wish list for company behavior” for improving access to medicine.
Continue reading
Les Groupes Suisses Doivent Faciliter L’accès Aux Médicaments

Les groupes suisses doivent faciliter l’accès aux médicaments

Writing in Le Temps, Index team members Damiano de Felice and Jayasree K. Iyer (Head of Research) give an overview of how Swiss policy and Swiss pharmaceutical companies are addressing access to medicine.
Continue reading
Is The Pharmaceutical Industry Improving With Regard To Access To Essential Medicines

Is the pharmaceutical industry improving with regard to access to essential medicines

Writing in The Lancet Global Health, Professor Hans Hogerzeil and members of the Index Research Team set out the findings of the first longitudinal analysis based on the Access to Medicine Index. Hans V. Hogerzeil who currently chairs the Expert Review Committee for the Access to Medicine Index.
Continue reading
Beloon Big Pharma Voor Goed Gedrag

Beloon Big Pharma voor goed gedrag

In NRC Next, Wim Leereveld's opiniated article, on how to influence pharmaceutical companies policies and practices to increase access to medicine, was published. NRC Next is a Dutch daily, that specifically targets a younger, well educated audience. The article refers to 'Morgen 2011' (Tomorrow 2011), where Wim is one of speakers at May 21, 2011.
Continue reading

Sign up to receive updates about our work.